Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag plus immunosuppressive therapy versus immunosuppressive therapy alone in treatment‑naive severe aplastic anemia (retrospective study)
ChiCTR2200060098Phase 4Not yet recruiting
- Sponsor
- Zhejiang Hospital of Traditional Chinese Medicine
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of eltrombopag in aplastic anemia (2 arms), sponsored by Zhejiang Hospital of Traditional Chinese Medicine. Primary endpoints: Hematology and Bone marrow routine. Planned start May 2022; status: not yet recruiting.
02
Drugs
eltrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on ChiCTR2200060098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060098.